Skip to content
Nonprofiteer
← All organizations

DAVOS ALZHEIMERS COLLABORATIVE INC

EIN 86-1884515 WAYNE, PA

Revenue 2025
$12,470,622
Expenses 2025
$16,083,398

Program services were 92.2% of total expenses calculated — Part IX's program-services column over total expenses, both as filed.

As filed

Subsection
03
NTEE code
G83
Classification
1000
Street
155 E LANCASTER AVE

These codes are the IRS's own and are shown exactly as filed. What each one means is in the Business Master File documentation (opens in a new tab).

Mission and programs · 2025

Mission

DAC IS LEADING THE LARGEST GLOBAL RESPONSE OF ITS KIND, DRIVING SCIENTIFIC DISCOVERY AND ALIGNING HEALTH SYSTEMS TO HELP PEOPLE WORLDWIDE, INCLUDING THOSE IN LOW RESOURCED ENVIRONMENTS LEFT OUT OF PREVIOUS EFFORTS TO FIGHT ALZHEIMER'S. (SEE SCHEDULE O)WE ARE COMMITTED TO TRANSFORMING ALZHEIMER'S RESEARCH, PREVENTION AND CARE THROUGH PROVEN PRIVATE-PUBLIC MODELS, SUCH AS GAVI, CEPI AND THE GLOBAL FUND.

Activities or mission (Part I)

SEE PART III LINE 1.

  • THE DAVOS ALZHEIMER'S COLLABORATIVE'S SYSTEM PREPAREDNESS PROGRAM AIMS TO STRENGTHEN HEALTHCARE SYSTEMS' ABILITY TO IDENTIFY AND ADDRESS ALZHEIMER'S DISEASE (AD) AND RELATED DEMENTIAS (ADRD) EARLY. KEY INITIATIVES INCLUDE THE EARLY DETECTION FELLOWSHIP, WHICH OFFERS TECHNICAL ASSISTANCE AND FUNDING TO HEALTHCARE ORGANIZATIONS (HCOS) TO IMPLEMENT THE EARLY DETECTION BLUEPRINT, FOSTERING COLLABORATION AMONG SELECTED SITES TO OVERCOME BARRIERS AND ENHANCE EARLY DETECTION. THE PROGRAM ALSO INCLUDES THE BRAIN HEALTH NAVIGATOR INITIATIVE, DESIGNED TO PILOT A BRAIN HEALTH NAVIGATOR MODEL IN SIX HCOS TO SUPPORT TIMELY CARE FOR PATIENTS WITH COGNITIVE DECLINE. ADDITIONALLY, THE ACCURATE DIAGNOSIS PROGRAM AIMS TO INCREASE THE USE OF NEW DIAGNOSTIC TOOLS, HELPING HEALTHCARE SYSTEMS ADOPT MORE EFFECTIVE METHODS FOR DIAGNOSING AD/ADRD. THESE EFFORTS ARE SUPPORTED BY SIGNIFICANT FUNDING AND ARE INTENDED TO IMPROVE SYSTEM PREPAREDNESS THROUGH OUTREACH, TRAINING, AND THE CREATION OF PRACTICAL TOOLKITS FOR HEALTHCARE PROVIDERS.OVERALL, OUTPUTS INCLUDE PEER-REVIEWED PUBLICATIONS, SYMPOSIUMS, POLICY COMMUNICATIONS, AND AN OPEN-ACCESS "BLUEPRINT" FOR AD/ADRD EARLY DETECTION AND SYSTEM PREPAREDNESS. DAC ALSO COLLABORATES WITH OTHER ORGANIZATIONS TO ADDRESS COMMON BARRIERS AND PROMOTE BEST PRACTICES ACROSS HEALTH SYSTEMS.

    Expenses $13,167,569 · Grants $3,538,155

  • THE DAVOS ALZHEIMER'S COLLABORATIVE'S GLOBAL COHORT DEVELOPMENT PROGRAM FOCUSES ON BUILDING A DIVERSE AND SUSTAINABLE NETWORK OF COHORTS TO ADVANCE ALZHEIMER'S DISEASE (AD) AND RELATED DEMENTIAS (ADRD) RESEARCH. THIS INCLUDES PARTNERSHIPS SUCH AS THE COLLABORATION WITH AGA KHAN UNIVERSITY IN NAIROBI, KENYA, WHERE COGNITIVE TESTS, SALIVA-BASED POLYGENIC RISK SCORES, AND DIGITAL COGNITIVE ASSESSMENTS ARE BEING VALIDATED IN EAST AFRICAN POPULATIONS TO CREATE A CLINICAL TRIAL-READY COHORT. IN SOUTH KOREA, DAC HAS ACQUIRED BLOOD SAMPLES FROM 300 PARTICIPANTS IN A HIGHLY CHARACTERIZED COHORT, ADVANCING THE VALIDATION OF BLOOD-BASED BIOMARKERS (BBMS) FOR GLOBAL USE. THE PROJECT ALSO INCLUDES ACCESS TO 1,000 BLOOD SAMPLES FROM A LONG-STANDING COHORT IN THE LATAM/CARIBBEAN REGION FOR AD BLOOD BIOMARKER VALIDATION, AS WELL AS A LARGE-SCALE CLINICAL TRIAL RECRUITMENT EFFORT IN THE DOMINICAN REPUBLIC, WITH OVER 14,000 PARTICIPANTS ACROSS URBAN AND RURAL SETTINGS.FURTHER EXPANDING GLOBAL RESEARCH, DAC IS DEVELOPING SCALABLE APPROACHES IN EGYPT FOR EARLY DETECTION, MONITORING, AND RISK REDUCTION OF AD, WHILE IN INDIA, THE "EYE-DEA STUDY" IS USING CATARACT SURGERY CLINICS TO ASSESS OCULAR, SPEECH, AND OLFACTORY BIOMARKERS RELATED TO COGNITIVE IMPAIRMENT. IN CHILE, DAC IS COLLECTING A WIDE RANGE OF DATA FROM A 9,000-PERSON COHORT TO GENERATE LOCAL VALIDATION DATA FOR BLOOD BIOMARKERS AND DIGITAL COGNITIVE ASSESSMENTS, PARTICULARLY FOCUSING ON THE IMPACT OF PESTICIDE USE AND EXPOSURE TO NEUROTOXINS. THESE EFFORTS ARE HELPING TO ENSURE THAT AD RESEARCH IS INCLUSIVE OF DIVERSE POPULATIONS AND ADAPTABLE TO LOCAL SETTINGS, WITH THE AIM OF IMPROVING EARLY DETECTION, DIAGNOSIS, AND TREATMENT ON A GLOBAL SCALE.

    Expenses $1,667,040 · Grants $4,000 · Revenue $60,000

  • THE DAVOS ALZHEIMER'S COLLABORATIVE'S GLOBAL CLINICAL TRIAL PROGRAM IS MAINTAINING A NETWORK OF MORE THAN 30 EUROPEAN SITES ORGANIZED TO ACCELERATE STUDIES AND IMPLEMENT NOVEL TRIAL DESIGNS. THIS EFFORT IS PART OF DAC'S BROADER GOAL TO BUILD INFRASTRUCTURE FOR FUTURE PHARMACOLOGICAL AND NON-PHARMACOLOGICAL TRIALS GLOBALLY. THROUGH THE GLOBAL COHORT DEVELOPMENT PROGRAM, DAC IS WORKING TO CREATE CLINICAL TRIAL-READY POPULATIONS BY 2026, ENSURING THAT DIVERSE AND WELL-CHARACTERIZED COHORTS ARE PREPARED FOR BOTH TYPES OF INTERVENTIONS. THIS WILL EXPAND OPPORTUNITIES FOR GLOBAL CLINICAL TRIALS, ENHANCING THE ABILITY TO TEST NEW TREATMENTS AND APPROACHES IN ALZHEIMER'S DISEASE (AD) AND RELATED DEMENTIAS (ADRD) ACROSS VARIED POPULATIONS AND SETTINGS.

As filed on the 2025 return. The filer continues this part on Schedule O, which is not shown here.

Officers and directors · 2025

As listed in Part VII of the 2025 return, in the order the filer printed them. Each return names its own; this is not a roster the organization keeps with us.

  • GEORGE VRADENBURG

    CHAIR & PRESIDENT

    Total calculated
    $0
    Hours/week
    20 + 2 related

  • ANDREW HOLZAPFEL

    COO (SEE SCHEDULE O)

    Total calculated
    $0
    Hours/week
    30 + 3 related

  • FREDA LEWIS HALL

    TREASURER

    Total calculated
    $0
    Hours/week
    1 + 1 related

Compensation is as filed in Part VII: reportable pay from this organization and from related organizations, other compensation, and hours per week. The total, marked calculated, is our sum of the three dollar columns, with a blank column counted as $0; the form itself has no total. On a Form 990-EZ the columns are Part IV's instead, and on a Form 990-PF Part VIII's — compensation, contributions to benefit plans, and expense account — and the total sums those. Earlier years are each on their own filing page.

Filings

  • 2025
    Revenue
    $12,470,622
    Expenses
    $16,083,398
    Contributions
    $12,186,383
    Grants paid
    $3,542,155
  • 2023
    Revenue
    $8,484,685
    Expenses
    $9,009,933
    Contributions
    $8,484,685
    Grants paid
    $1,996,537
  • 2022
    Revenue
    $9,767,900
    Expenses
    $8,101,186
    Contributions
    $9,767,900
    Grants paid
    $2,919,719

The four totals the IRS asks for on Part I of the Form 990, as filed. A dash means the figure was not present on the return — not that it was zero.

Other returns filed

  • 2021 · 990

    Revenue
    $14,514,120
    Expenses
    $2,767,999
    Assets (EOY)
    $12,443,051

Nonprofiteer parses Forms 990, 990-EZ and 990-PF, in a window of recent tax years. These returns are recorded from the IRS e-file index, so their figures were extracted by that index rather than read from the return here — treat them as a different source from the filings above, not as more of the same record. A dash means the index carries no figure; Form 990-T listings carry none at all.

Grants made

The 10 largest by cash amount. The API serves every itemized grant.

Where these grants went next →

Grants received

Related organizations

From Schedule R Part II, where a filer lists the tax-exempt organizations it is related to by control. It does not record shared board members or money.

Declared on its 2025 return

  • DAVOS ALZHEIMER'S COLLABORATIVE (GENEVE)

    N/A · PROMOTE HEALTH BY DEVELOPING RESEARCH ON BRAIN HEALTH.. · SZ · controlled entity

Other IRS files

Auto-Revocation List

Not listed. The IRS publishes this list for organizations whose exemption was automatically revoked for failing to file for three consecutive years.

Publication 78

Listed as of 13 October 2026, under deductibility PC.

These are two separate IRS files on two separate schedules, shown as published and not reconciled with each other. Neither is a statement about whether a contribution is deductible today: 19,245 organizations appear in Publication 78 while the IRS's own revocation file lists them as currently revoked, more than half of those revoked before 2019. Absence from Publication 78 is evidence of nothing, and presence is not evidence either. Verify current status with the IRS before relying on it.

What this page reflects

The registration facts above come from the IRS Business Master File published 13 October 2026 and read 26 October 2026, for every organization at once. Returns through tax year 2025, the newest we have parsed for this organization.